Get started
Author

Thomas G Martin

Observed names: T Martin, T. Martin, Thomas G. Martin, Thomas Martin
ORCID: 0000-0003-1752-5092
Observed ORCID: 0000-0003-1752-5092
OpenAlex ID: A5091675809
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
2013 · D. Siegel, T. Martin, et al. · Haematologica · 347
PDF
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
2022 · Noopur S Raje, Elias Anaissie, et al. · The Lancet Haematology · 210
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
2023 · Ajay K. Nooka, Cesar Rodriguez, et al. · Cancer · 96
PDF
Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
2024 · Alfred L. Garfall, Ajay K. Nooka, et al. · Journal of Clinical Oncology · 92
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma
2023 · Thomas G. Martin, Maria Victoria Mateos, et al. · Cancer · 72
PDF
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
2019 · Jonathan L. Kaufman, Roberto Mina, et al. · Blood Cancer Journal · 53
PDF
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
2023 · Noffar Bar, Maria Victoria Mateos, et al. · Blood · 33
Isatuximab Plus Carfilzomib and Dexamethasone Vs Carfilzomib and Dexamethasone in Relapsed/refractory Multiple Myeloma (ikema): Interim Analysis of a Phase 3, Randomized, Open-label Study
2020 · A. Maiolino, P. Moreau, et al. · Hematology Transfusion and Cell Therapy · 32
Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies
2024 · Anita D'Souza, Luciano J. Costa, et al. · Blood · 28
Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
2010 · A. Z. Badros, R. Vij, et al. · Journal of Clinical Oncology · 21
Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).
2011 · M. Wang, W. Bensinger, et al. · Journal of Clinical Oncology · 19
Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
2013 · Thomas G Martin · PubMed · 17
Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
2021 · Thomas G. Martin, Nina Shah, et al. · Cancer · 13
PDF
MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Alfred L Garfall, Ajay K Nooka, et al. · Clinical Lymphoma Myeloma & Leukemia · 10
Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
2010 · W. Bensinger, M. Wang, et al. · Journal of Clinical Oncology · 10
Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
2020 · M. Turgut, P. Moreau, et al. · Hematology Transfusion and Cell Therapy · 9
PDF
PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.
2011 · D. S. D. Siegel, T. Martin, et al. · Journal of Clinical Oncology · 9
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis
2025 · Hira Mian, Thomas G. Martin, et al. · Leukemia · 7
Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
2024 · Murali Janakiram, Carlyn Rose Tan, et al. · Blood · 4
PDF
Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Alfred L Garfall, Ajay K Nooka, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma
2024 · Chandramouli Nagarajan, Martin Wong Eu Jo, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
P06: Updated Results From the Phase 1/2 Majestec-1 Study of Teclistamab, a B-cell Maturation Antigen X Cd3 Bispecific Antibody, in Patients With Relapsed/refractory Multiple Myeloma
2022 · R Popat, S Usmani, et al. · HemaSphere · 3
Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)
2024 · David H. Vesole, Thomas G Martin, et al. · Blood · 2
PDF
Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma
2025 · Nikhil Chilakapati, Bonell Patiño-Escobar, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2024 · William A. Wood, Emily A. Semmel, et al. · Blood · 1
Works count: 35
Citation count: 1,100
H-index: 13
I10-index: 15
Year
Topic
Type